23 October 2026 ASX Announcement September 2026 Quarterly Activity Report Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to provide its business activity update for the quarter ending 30 September 2026, along with its Appendix 4C quarterly cash flow report. REVIEW OF QUARTERLY...
September 2026 Quarterly Activity Report & Appendix 4C
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The company is entering the US retail pharmacy market with its Nasodine products, following strong online sales growth and participation in a major retail trade expo. Cash operating expenses decreased compared to the previous quarter, primarily due to lower research and development costs, while sales receipts showed a seasonal decline but continued to grow annually. The report includes a compliance statement confirming adherence to accounting standards and provides insights into the company's cash position and activities during the quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- New Product - Nasodine Sinus Rinse
- Change in substantial holding - Pharma Nutria
- Cleansing Notice
- Application for quotation of securities - FRE
- Nasodine Nasal Spray Approved in the Philippines
Later from Firebrick Pharma
- Results of Annual General Meeting
- Proposed issue of securities - FRE
- Change of Director's Interest Notice - Al Moghaddam
- Change of Director's Interest Notice - Peter Molloy
- Change of Director's Interest Notice - Rick Legleiter
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma